MetaLabs Co., Ltd.

As of June 30, 2026, MetaLabs Co., Ltd. carries a market capitalization of 27.52B, placing it among publicly traded companies globally. Its enterprise value stands at 186.23B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, MetaLabs Co., Ltd. has 24.90M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.23, and the price-to-book ratio stands at 0.32.

As of June 30, 2026, MetaLabs Co., Ltd. trades at an EV/EBITDA multiple of 52.62 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 186.23B versus a market cap of 27.52B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, MetaLabs Co., Ltd. maintains a current ratio of 0.44, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, MetaLabs Co., Ltd. posted a negative return on equity (ROE) of -7.40, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.13, reflecting losses generated across the asset base. The company generates approximately 6.62B in revenue per employee across its workforce of 18.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 41.50 indicates how many times MetaLabs Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, MetaLabs Co., Ltd. recorded 54.21M in income tax expense. The company reported a pretax loss of -6.91B and -5.90B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, MetaLabs Co., Ltd.'s stock has declined approximately 15.52% over the past 52 weeks. The 50-day moving average sits at 1,147.46, while the 200-day moving average is 1,322.51.

Over the twelve months ended June 30, 2026, MetaLabs Co., Ltd. generated 119.11B in revenue and converted that into -5.90B in net income, yielding earnings per share of -278.61. EBITDA reached 3.54B, while operating income came in at -537.39M.

As of June 30, 2026, MetaLabs Co., Ltd. holds 12.83B in cash and equivalents against 102.12B in total debt, resulting in a net debt position of 87.09B. Total book value stands at 86.30B, with working capital of -73.34B providing operational flexibility.

MetaLabs Co., Ltd. produced 3.47B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -577.07M in capital expenditures, free cash flow totaled 2.89B - equivalent to 115.73 per share.

Over the twelve months ended June 30, 2026, MetaLabs Co., Ltd. posted a gross margin of 14.45, reflecting its pricing power and cost economics. The operating margin of -0.45 and net profit margin of -4.95 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 10.47, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 9.81, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to MetaLabs Co., Ltd. shareholders.

MetaLabs Co., Ltd.'s most recent stock split took place on December 2, 2022 with a 5:1 split ratio.

As of June 30, 2026, MetaLabs Co., Ltd. has an Altman Z-Score of 0.21, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.